tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Denys-Drash Syndrome D030321 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Leukoplakia D007971 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Mediastinitis D008480 2 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ileus D045823 3 associated lipids
Rectal Diseases D012002 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Qin J et al. Radiological and clinical findings of 25 patients with invasive pulmonary aspergillosis: retrospective analysis of 2150 liver transplantation cases. 2012 Br J Radiol pmid:22496071
Ahn KJ et al. Diffusion-weighted MRI and ADC mapping in FK506 neurotoxicity. 2003 Br J Radiol pmid:14711782
Murphy GJ et al. Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis. 2003 Br J Surg pmid:12808614
Middleton SJ et al. Adult small intestinal transplantation in England and Wales. 2003 Br J Surg pmid:12808622
Morris-Stiff GJ et al. Sequential changes in plasma selenium concentration after cadaveric renal transplantation. 2004 Br J Surg pmid:14991636
Wilson CH et al. Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants. 2005 Br J Surg pmid:15856479
Waller JR et al. Effects of the combination of rapamycin with tacrolimus or cyclosporin on experimental intimal hyperplasia. 2002 Br J Surg pmid:12390379
Brook NR et al. Fibrosis-associated gene expression in renal transplant glomeruli after acute renal allograft rejection. 2003 Br J Surg pmid:12905557
Jain S et al. Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury. 2000 Br J Surg pmid:11091246
Bicknell GR et al. Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants. 2000 Br J Surg pmid:11091247
White DJ Immunosuppression for heart transplantation. 1993 Br. J. Biomed. Sci. pmid:7694717
Reichert TE et al. The role of endogenous interleukin-2 in proliferation of human carcinoma cell lines. 1999 Br. J. Cancer pmid:10555752
Andersson Y et al. Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo. 2009 Br. J. Cancer pmid:19773757
Chambers CA Topical tacrolimus for cutaneous lupus erythematosus. 2003 Br. J. Dermatol. pmid:12752154
Ludwig E et al. New treatment modalities for granuloma faciale. 2003 Br. J. Dermatol. pmid:14511001
Vecchietti G et al. Topical tacrolimus (FK506) for relapsing erosive stomatitis in paraneoplastic pemphigus. 2003 Br. J. Dermatol. pmid:12752158
Bens G et al. Topical treatment of Netherton's syndrome with tacrolimus ointment without significant systemic absorption. 2003 Br. J. Dermatol. pmid:12890237
Reich K et al. Topical tacrolimus for pyoderma gangrenosum. 1998 Br. J. Dermatol. pmid:9892935
Danby SG and Cork MJ The effects of pimecrolimus on the innate immune response in atopic dermatitis. 2013 Br. J. Dermatol. pmid:23362967
Schmitt J et al. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. 2011 Br. J. Dermatol. pmid:20819086
Sugiura H et al. An open study of a lotion formulation to improve tolerance of tacrolimus in facial atopic dermatitis. 2001 Br. J. Dermatol. pmid:11736904
Calza AM and Lübbe J Tacrolimus ointment-associated alcohol intolerance in infants receiving ethanol-containing medication. 2005 Br. J. Dermatol. pmid:15787832
Rigopoulos D et al. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. 2004 Br. J. Dermatol. pmid:15541087
Clayton TH and Harrison PV Successful treatment of chronic ulcerated necrobiosis lipoidica with 0.1% topical tacrolimus ointment. 2005 Br. J. Dermatol. pmid:15787840
Rodríguez García F et al. Generalized pustular psoriasis successfully treated with topical tacrolimus. 2005 Br. J. Dermatol. pmid:15787845
Remitz A et al. Tacrolimus ointment improves psoriasis in a microplaque assay. 1999 Br. J. Dermatol. pmid:10417522
Braza TJ et al. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. 2003 Br. J. Dermatol. pmid:12828755
Danby SG et al. The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. 2014 Br. J. Dermatol. pmid:24328907
Weidinger S et al. A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal. 2017 Br. J. Dermatol. pmid:28868633
Charman C A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - comment. 2017 Br. J. Dermatol. pmid:28858382
Lan CC et al. FK506 (tacrolimus) and endothelin combined treatment induces mobility of melanoblasts: new insights into follicular vitiligo repigmentation induced by topical tacrolimus on sun-exposed skin. 2011 Br. J. Dermatol. pmid:21039414
Esquivel-Pedraza L et al. Treatment of oral lichen planus with topical pimecrolimus 1% cream. 2004 Br. J. Dermatol. pmid:15099380
Sorgentini C et al. Lichen striatus in an adult: successful treatment with tacrolimus. 2004 Br. J. Dermatol. pmid:15099383
Dissemond J et al. Pimecrolimus in an adhesive ointment as a new treatment option for oral lichen planus. 2004 Br. J. Dermatol. pmid:15099387
Harth W and Linse R Topical tacrolimus in granuloma annulare and necrobiosis lipoidica. 2004 Br. J. Dermatol. pmid:15099394
Kanekura T et al. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. 2003 Br. J. Dermatol. pmid:12588393
Vente C et al. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. 1999 Br. J. Dermatol. pmid:10233234
Lyon CC et al. Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. 1999 Br. J. Dermatol. pmid:10233300
Jolles S et al. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. 1999 Br. J. Dermatol. pmid:10233301
Anstey A Therapeutic advances and shift in disease paradigm for atopic dermatitis. 2008 Br. J. Dermatol. pmid:19036027
Koguchi-Yoshioka H et al. Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules/papules. 2017 Br. J. Dermatol. pmid:28346662
Griffiths CE Ascomycin: an advance in the management of atopic dermatitis. 2001 Br. J. Dermatol. pmid:11298524
Fujimoto N et al. Facial lichen striatus: successful treatment with tacrolimus ointment. 2003 Br. J. Dermatol. pmid:12653755
Harper J et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. 2001 Br. J. Dermatol. pmid:11298537
Ueda M et al. Successful treatment of amyopathic dermatomyositis with topical tacrolimus. 2003 Br. J. Dermatol. pmid:12653761
Luger T et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. 2001 Br. J. Dermatol. pmid:11298538
Lan CC et al. FK506 independently upregulates transforming growth factor beta and downregulates inducible nitric oxide synthase in cultured human keratinocytes: possible mechanisms of how tacrolimus ointment interacts with atopic skin. 2004 Br. J. Dermatol. pmid:15377358
Fricain JC et al. Long-term efficacy of topical tacrolimus on oral lesions of chronic graft-versus-host disease. 2007 Br. J. Dermatol. pmid:17300261
Vissers WH et al. Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression. 2008 Br. J. Dermatol. pmid:18284400
Reitamo S et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. 2004 Br. J. Dermatol. pmid:15030341
Chuh AA The application of topical tacrolimus in vesicular pemphigoid. 2004 Br. J. Dermatol. pmid:15030368
Ormerod AD Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? 2005 Br. J. Dermatol. pmid:16181449
Lan CC et al. FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factor-kappaB. 2005 Br. J. Dermatol. pmid:16181452
Vukmanovic-Stejic M et al. Relative impact of CD4+CD25+ regulatory T cells and tacrolimus on inhibition of T-cell proliferation in patients with atopic dermatitis. 2005 Br. J. Dermatol. pmid:16181456
Martin-Munoz MF et al. Topical treatment tacrolimus and food allergy. 2005 Br. J. Dermatol. pmid:16181473
Gollnick H et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. 2008 Br. J. Dermatol. pmid:18341665
Hjelmgren J et al. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data. 2007 Br. J. Dermatol. pmid:17263826
Reitamo S et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. 2008 Br. J. Dermatol. pmid:18637898
Rigopoulos D et al. Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. 2009 Br. J. Dermatol. pmid:19120329
Oranje AP et al. Wet-wrap treatment using dilutions of tacrolimus ointment and fluticasone propionate cream in human APOC1 (+/+) mice with atopic dermatitis. 2009 Br. J. Dermatol. pmid:18795918
Wataya-Kaneda M et al. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. 2011 Br. J. Dermatol. pmid:21692771
Spergel JM et al. Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. 2007 Br. J. Dermatol. pmid:17573885
Bäumer W et al. Cilomilast, tacrolimus and rapamycin modulate dendritic cell function in the elicitation phase of allergic contact dermatitis. 2005 Br. J. Dermatol. pmid:16029339
Niwa Y et al. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. 2003 Br. J. Dermatol. pmid:14632799
Ko MJ and Chu CY Topical tacrolimus therapy for localized bullous pemphigoid. 2003 Br. J. Dermatol. pmid:14632824
Wollenberg A et al. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. 2008 Br. J. Dermatol. pmid:18782316
Doss N et al. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. 2009 Br. J. Dermatol. pmid:19416227
Thaçi D et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. 2008 Br. J. Dermatol. pmid:18782319
Böhm M et al. Resolution of lichen aureus in a 10-year-old child after topical pimecrolimus. 2004 Br. J. Dermatol. pmid:15327576
Leung DY et al. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial. 2009 Br. J. Dermatol. pmid:19416245
Hickey JR et al. Does topical tacrolimus induce lentigines in children with atopic dermatitis? A report of three cases. 2005 Br. J. Dermatol. pmid:15656817
Mancuso G and Berdondini RM Localized scleroderma: response to occlusive treatment with tacrolimus ointment. 2005 Br. J. Dermatol. pmid:15656828
Langeland T and Engh V Topical use of tacrolimus and squamous cell carcinoma on the penis. 2005 Br. J. Dermatol. pmid:15656830
Kreuter A et al. Pimecrolimus 1% cream for perianal atopic dermatitis. 2005 Br. J. Dermatol. pmid:15656832
Fiorentino DF et al. The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes. 2011 Br. J. Dermatol. pmid:21166661
Lewis FM and Neill SM Safety of calcineurin inhibitors in the management of lichen sclerosis. 2007 Br. J. Dermatol. pmid:17535239
Neckermann G et al. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. 2000 Br. J. Dermatol. pmid:10792216
Queille-Roussel C et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. 2001 Br. J. Dermatol. pmid:11260007
Ramsay HM and Harden PN Cyclosporin-induced flushing in a renal transplant recipient resolving after substitution with tacrolimus. 2000 Br. J. Dermatol. pmid:10792253
Rao A and Bunker C Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. 2010 Br. J. Dermatol. pmid:20353455
Ellis C et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. 2003 Br. J. Dermatol. pmid:12694268
Oji V et al. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. 2005 Br. J. Dermatol. pmid:16225628
Connolly M and Kennedy C Exfoliative cheilitis successfully treated with topical tacrolimus. 2004 Br. J. Dermatol. pmid:15270904
Healy E et al. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. 2011 Br. J. Dermatol. pmid:21083544
Tzung TY and Wu JC Topical calcineurin inhibitors in treating Jessner's lymphocytic infiltration of the skin: report of a case. 2005 Br. J. Dermatol. pmid:15727667
Poole CD et al. Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study. 2009 Br. J. Dermatol. pmid:19754867
Chu CY The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. 2005 Br. J. Dermatol. pmid:15727676
Park CW et al. Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. 2005 Br. J. Dermatol. pmid:15948978
Gottlieb AB et al. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. 2005 Br. J. Dermatol. pmid:15948985
Bhol KC and Schechter PJ Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. 2005 Br. J. Dermatol. pmid:15948987
Reitamo S et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. 2005 Br. J. Dermatol. pmid:15948994
Bos JD Topical tacrolimus and pimecrolimus are not associated with skin atrophy. 2002 Br. J. Dermatol. pmid:11903264
Wolff K et al. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. 2005 Br. J. Dermatol. pmid:15948996
Rigopoulos D et al. Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. 2005 Br. J. Dermatol. pmid:15949015
Kirtschig G et al. Successful treatment of erosive vulvovaginal lichen planus with topical tacrolimus. 2002 Br. J. Dermatol. pmid:12207624
Feldmann KA et al. Is topical tacrolimus effective in alopecia areata universalis? 2002 Br. J. Dermatol. pmid:12410729
Sigurgeirsson B and Luger T A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - author response. 2017 Br. J. Dermatol. pmid:28940181
Ho N et al. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo. 2011 Br. J. Dermatol. pmid:21457214
Rigopoulos D et al. Tacrolimus ointment 0.1% in pityriasis alba: an open-label, randomized, placebo-controlled study. 2006 Br. J. Dermatol. pmid:16792767
Weissenbacher S et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. 2007 Br. J. Dermatol. pmid:17493072